Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol

M Aryana Bryan, Marcela C Smid, Melissa Cheng, Katherine T Fortenberry, Amy Kenney, Bhanu Muniyappa, Danielle Pendergrass, Adam J Gordon, Gerald Cochran, M Aryana Bryan, Marcela C Smid, Melissa Cheng, Katherine T Fortenberry, Amy Kenney, Bhanu Muniyappa, Danielle Pendergrass, Adam J Gordon, Gerald Cochran

Abstract

Background: Opioid use disorder (OUD) among women delivering at a hospital has increased 400% from 1999-2014 in the United States. From the years 2007 to 2016, opioid-related mortality during pregnancy increased over 200%, and drug-overdose deaths made up nearly 10% of all pregnancy-associated mortality in 2016 in the US. Disproportionately higher rates of neonatal opioid withdrawal syndrome (NOWS) have been reported in rural areas of the country, suggesting that perinatal OUD is a pressing issue among these communities. There is an urgent need for comprehensive, evidence-based treatment services for pregnant women experiencing OUD. The purpose of this article is to describe a study protocol aimed at developing and evaluating a perinatal OUD curriculum, enhancing evidence-based perinatal OUD treatment in a rural setting, and evaluating the implementation of such collaborative care for perinatal OUD.

Methods: This two-year study employed a one group, repeated measures, hybrid type-1 effectiveness-implementation design. This study delivered interventions at 2 levels, both targeting improvement of care for pregnant women with OUD. The first area of focus was at the community healthcare provider-level, which aimed to evaluate the acceptability and feasibility of perinatal OUD education across time and to improve provider education by increasing knowledge specific to: MOUD provision; screening, brief intervention, and referral to treatment (SBIRT) utilization; and NOWS treatment. The second area of intervention focus was at the patient-level, which assessed the preliminary effect of perinatal OUD provider education in promoting illicit opioid abstinence and treatment engagement among pregnant women with OUD. We adopted constructs from the Consolidated Framework for Implementation Research (CFIR) to assess contextual factors that may influence implementation, and the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) model to comprehensively evaluate implementation outcomes.

Discussion: This article presents the protocol of an implementation study that is employing the CFIR and RE-AIM frameworks to implement and evaluate a perinatal OUD education and service coordination program in two rural counties. This protocol could serve as a model for clinicians and researchers seeking to implement improvements in perinatal care for women with OUD in other rural communities. Trial registration NCT04448015 clinicaltrials.gov.

Keywords: Medication for opioid use disorder; Medication-assisted treatment; Opioid use disorder; Perinatal addiction; Provider education; Rural.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999–2014. MMWR Morb Mortal Wkly Rep. 2018;67(31):845–849. doi: 10.15585/mmwr.mm6731a1.
    1. Gemmill A, Kiang MV, Alexander MJ. Trends in pregnancy-associated mortality involving opioids in the United States, 2007–2016. Am J Obstet Gynecol. 2019;220(1):115–116. doi: 10.1016/j.ajog.2018.09.028.
    1. Smid MC, Stone NM, Baksh L, Debbink MP, Einerson BD, Varner MW, et al. Pregnancy-associated death in utah: contribution of drug-induced deaths. Obstet Gynecol. 2019;133(6):1131–1140. doi: 10.1097/AOG.0000000000003279.
    1. Smid MC, Maeda J, Stone NM, Sylvester H, Baksh L, Debbink MP, et al. Standardized criteria for review of perinatal suicides and accidental drug-related deaths. Obstet Gynecol. 2020;136:645–653. doi: 10.1097/AOG.0000000000003988.
    1. Brown JD, Goodin AJ, Talbert JC. Rural and appalachian disparities in neonatal abstinence syndrome incidence and access to opioid abuse treatment. J Rural Health. 2018;34(1):6–13. doi: 10.1111/jrh.12251.
    1. ACOG Committee Opinion No 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070–1076. doi: 10.1097/AOG.0b013e318256496e.
    1. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. J Addict. 2012;107:5–27. doi: 10.1111/j.1360-0443.2012.04035.x.
    1. McQueen KA, Murphy-Oikonen J, Gerlach K, Montelpare W. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care. 2011;11(4):282–290. doi: 10.1097/ANC.0b013e318225a30c.
    1. Shainker SA, Saia K, Lee-Parritz A. Opioid addiction in pregnancy. Obstet Gynecol Surv. 2012;67(12):817–825. doi: 10.1097/OGX.0b013e3182788e8c.
    1. Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HMJJop. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. 2014;2014.
    1. Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol. 2018;132(2):466–474. doi: 10.1097/AOG.0000000000002734.
    1. Committee Opinion No 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):e81–e94. doi: 10.1097/AOG.0000000000002235.
    1. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107(Suppl 1):5–27. doi: 10.1111/j.1360-0443.2012.04035.x.
    1. Keough L, Fantasia HC. Pharmacologic treatment of opioid addiction during pregnancy. Nurs Womens Health. 2017;21(1):34–44. doi: 10.1016/j.nwh.2016.12.010.
    1. Haug NA, Duffy M, McCaul ME. Substance abuse treatment services for pregnant women: psychosocial and behavioral approaches. Obstet Gynecol Clin North Am. 2014;41(2):267–296. doi: 10.1016/j.ogc.2014.03.001.
    1. Villapiano NL, Winkelman TN, Kozhimannil KB, Davis MM, Patrick SW. Rural and urban differences in neonatal abstinence syndrome and maternal opioid use , 2004 to 2013. JAMA Pediatrics. 2017;171(2):194–196. doi: 10.1001/jamapediatrics.2016.3750.
    1. Martin CE, Longinaker N, Terplan M. Recent trends in treatment admissions for prescription opioid abuse during pregnancy. J Subst Abuse Treat. 2014;48(1):37–42. doi: 10.1016/j.jsat.2014.07.007.
    1. Andrilla CH, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108–112. doi: 10.1111/jrh.12307.
    1. Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71(4):359–360. doi: 10.1001/jamapsychiatry.2013.4450.
    1. Patrick SW, Buntin MB, Martin PR, Scott TA, Dupont W, Richards M, et al. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states. Subst Abus. 2019;40(3):356–362. doi: 10.1080/08897077.2018.1488336.
    1. Villapiano NL, Winkelman TN, Kozhimannil KB, Davis MM, Patrick SW. Rural and urban differences in neonatal abstinence syndrome and maternal opioid use, 2004 to 2013. JAMA pediatrics. 2017;171(2):194–196. doi: 10.1001/jamapediatrics.2016.3750.
    1. Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. J Obstetrics Gynecol. 2016;128(1):4. doi: 10.1097/AOG.0000000000001446.
    1. Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113–121. doi: 10.1111/jrh.12328.
    1. Andrilla CHA, Coulthard C, Larson E. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017;15(4):359–362. doi: 10.1370/afm.2099.
    1. Andrilla C, Coulthard C, Larson E. Changes in the supply of physicians with a DEA DATA waiver to prescribe buprenorphine for opioid use disorder. Seattle: WAMI Rural Health Research Center; 2017.
    1. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(50):1–5.
    1. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–1327. doi: 10.2105/AJPH.89.9.1322.
    1. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217–226. doi: 10.1097/MLR.0b013e3182408812.
    1. The Henry J Kaiser Family Foundation. Opioid Overdose Deaths by Gender [Report on the Internet]. KFF; 2018. . Accessed 2 May 2019.
    1. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstetrics Gynecol. 2014;123(5):997. doi: 10.1097/AOG.0000000000000208.
    1. RHIhub. Am I Rural? [Report on Internet]. RHI; 2019 . Accessed 4 Nov 2019
    1. Vandenack T. Ogden ranks high in opioid overdose deaths, trails just Carbon, Emery counties. Standard-Examiner. 2019;1:2019.
    1. Murphy K. How Carbon County is 'building a fence' to protect the community from opioids. Deseret News. 2017; Sect. InDepth.
    1. Fondario A. Opioid Overdose Crisis in Carbon County. Department of Health; 2016.
    1. Callan LB. Adapting the windshield survey model to community health education. HSMHA Health Rep. 1971;86(3):202–203. doi: 10.2307/4594130.
    1. CFIR Research Team. Ann Abor: CFIR Guide. CFIR Domains; 2019. . Accessed 4 Nov 2019.
    1. Aarons G. Mental health provider attitudes toward adoption of evidence-based practice: the evidence-based practice attitude scale. Mental Health Serv Res. 2004;6(2):61–74. doi: 10.1023/B:MHSR.0000024351.12294.65.
    1. Venkat A, Aldridge A, Kearney S, Radack J, Richard-Aasen S, Grasso K, et al. Derivation of a shortened research instrument for measuring alcohol and other drug (AOD) attitudes in a screening, brief intervention, and referral to treatment (SBIRT) training program. J Sci, Human Arts. 2017;8:1–16.
    1. Anderson P, Clement S. The AAPPQ revisited: the measurement of general practitioners' attitudes to alcohol problems. Br J Addict. 1987;82(7):753–759. doi: 10.1111/j.1360-0443.1987.tb01542.x.
    1. Dawson DA, Grant BF, Stinson FS, Zhou Y. Effectiveness of the derived Alcohol Use Disorders Identification Test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. Alcohol Clin Exp Res. 2005;29(5):844–854. doi: 10.1097/01.ALC.0000164374.32229.A2.
    1. Tarrahi MJ, Rahimi-Movaghar A, Zeraati H, Motevalian SA, Amin-Esmaeili M, Hajebi A, et al. Latent class analysis of DSM-5 criteria for opioid use disorders: Results from the Iranian National Survey on Mental Health. Eur Addict Res. 2015;21(3):144–152. doi: 10.1159/000369338.
    1. Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF. Reliability of the fagerstrom tolerance questionnaire and the fagerstrom test for nicotine dependence. Addict Behav. 1994;19(1):33–39. doi: 10.1016/0306-4603(94)90049-3.
    1. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007;32(2):189–198. doi: 10.1016/j.jsat.2006.08.002.
    1. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression development of the 10-item edinburgh postnatal depression scale. Br J Psychiatry. 1987;150:782–786. doi: 10.1192/bjp.150.6.782.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Lowe B, Decker O, Muller S, Brahler E, Schellberg D, Herzog W, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46(3):266–274. doi: 10.1097/MLR.0b013e318160d093.
    1. Staples LG, Dear BF, Gandy M, Fogliati V, Fogliati R, Karin E, et al. Psychometric properties and clinical utility of brief measures of depression, anxiety, and general distress: The PHQ-2, GAD-2, and K-6. Gen Hosp Psychiatry. 2019;56:13–18. doi: 10.1016/j.genhosppsych.2018.11.003.
    1. Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233. doi: 10.1097/00005650-199603000-00003.
    1. Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med. 1998;14(4):245–258. doi: 10.1016/S0749-3797(98)00017-8.
    1. Prins A, Bovin MJ, Smolenski DJ, Marx BP, Kimerling R, Jenkins-Guarnieri MA, et al. The primary care PTSD screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample. J Gen Intern Med. 2016;31(10):1206–1211. doi: 10.1007/s11606-016-3703-5.
    1. Sanders MR, Morawska A, Haslam DM, Filus A, Fletcher R. Parenting and family adjustment scales (PAFAS): validation of a brief parent-report measure for use in assessment of parenting skills and family relationships. Child Psychiatry Hum Dev. 2014;45(3):255–272. doi: 10.1007/s10578-013-0397-3.
    1. Thayaparan AJ, Mahdi E. The patient satisfaction questionnaire short form (PSQ-18) as an adaptable, reliable, and validated tool for use in various settings. Med Educ Online. 2013;18:21747. doi: 10.3402/meo.v18i0.21747.
    1. Cacciola JS, Alterman AI, Lynch KG, Martin JM, Beauchamp ML, McLellan AT. Initial reliability and validity studies of the revised Treatment Services Review (TSR-6) Drug Alcohol Depend. 2008;92(1–3):37–47. doi: 10.1016/j.drugalcdep.2007.06.004.
    1. Finnegan LP, Connaughton JF, Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1–2):141–158.
    1. Bacchetti P. Peer review of statistics in medical research: the other problem. BMJ (Clinical research ed) 2002;324(7348):1271–1273. doi: 10.1136/bmj.324.7348.1271.
    1. Neal JW, Neal ZP, Vandyke E, Kornbluh M. Expediting the analysis of qualitative data in evaluation: a procedure for the rapid identification of themes from audio recordings (RITA) Am J Evaluat. 2015;36(1):118–132. doi: 10.1177/1098214014536601.
    1. Halcomb EJ, Davidson PM. Is verbatim transcription of interview data always necessary? Appl Nurs Res. 2006;19(1):38–42. doi: 10.1016/j.apnr.2005.06.001.
    1. Tessier S. From field notes, to transcripts, to tape recordings: evolution or combination? Int J Qualitat Methods. 2012;11(4):446–460. doi: 10.1177/160940691201100410.
    1. McNeely J, Troxel AB, Kunins HV, Shelley D, Lee JD, Walley A, et al. Study protocol for a pragmatic trial of the consult for addiction treatment and care in hospitals (CATCH) model for engaging patients in opioid use disorder treatment. Addict Sci Clin Pract. 2019;14(1):5. doi: 10.1186/s13722-019-0135-7.
    1. Tabak RG, Schwarz CD, Kemner A, Schechtman KB, Steger-May K, Byrth V, et al. Disseminating and implementing a lifestyle-based healthy weight program for mothers in a national organization: a study protocol for a cluster randomized trial. Implement Sci. 2019;14(1):68. doi: 10.1186/s13012-019-0916-0.
    1. King DK, Shoup JA, Raebel MA, Anderson CB, Wagner NM, Ritzwoller DP, et al. Planning for implementation success using re-aim and cfir frameworks: a qualitative study. Front Pub Health. 2020;8:59. doi: 10.3389/fpubh.2020.00059.
    1. Arrossi S, Paolino M, Orellana L, Thouyaret L, Kohler RE, Viswanath K. Mixed-methods approach to evaluate an mHealth intervention to increase adherence to triage of human papillomavirus-positive women who have performed self-collection (the ATICA study): study protocol for a hybrid type I cluster randomized effectiveness-implementation trial. Trials. 2019;20(1):148. doi: 10.1186/s13063-019-3229-3.
    1. Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157. doi: 10.1186/s12875-019-1047-z.
    1. Safaeinili N, Brown-Johnson C, Shaw JG, Mahoney M, Winget M. CFIR simplified: pragmatic application of and adaptations to the consolidated framework for implementation research (CFIR) for evaluation of a patient-centered care transformation within a learning health system. Learn Health Syst. 2020;4(1):e10201.
    1. Serhal E, Arena A, Sockalingam S, Mohri L, Crawford A. Adapting the consolidated framework for implementation research to create organizational readiness and implementation tools for project ECHO. J Cont Educat Health Profess. 2018;38(2):145–151. doi: 10.1097/CEH.0000000000000195.
    1. Lyden J, Binswanger IA. The United States opioid epidemic. Semin Perinatol. 2019;43(3):123–131. doi: 10.1053/j.semperi.2019.01.001.
    1. Terplan MJ. Women and the opioid crisis: historical context and public health solutions. Fertility Sterility. 2017;108(2):195–199. doi: 10.1016/j.fertnstert.2017.06.007.
    1. Stockwell S. Rural pregnant women and newborns hit hard by opioid crisis. Am J Nurs. 2017;117(3):17. doi: 10.1097/01.NAJ.0000513278.76259.6d.
    1. Rigg KK, Monnat SM, Chavez MN. Opioid-related mortality in rural America: Geographic heterogeneity and intervention strategies. Int J Drug Policy. 2018;57:119–129. doi: 10.1016/j.drugpo.2018.04.011.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel